Boy, was I wrong about Dendreon, analyst says

It isn't often that a Wall Street analyst admits to a mistake. But ISI Group's Mark Schoenebaum not only says he was wrong to be so optimistic about Dendreon ($DNDN) and its struggle to sell the prostate cancer treatment Provenge, he called it "the worst call of my 13 year career." Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.